Generex Biotechnology Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Generex Biotechnology Corporation
Torrent’s $245m acquisition of Curatio Healthcare has moved it up a rank to No.7 in the overall Indian pharmaceutical market apart from making it the market leader in cosmetic dermatology. While it’s a pricey deal, factors like growing prevalence of skin diseases and shift towards e-commerce bode well for future revenue growth in a nascent market
When the German major bought AskBio a couple of years ago, one of its assets was a gene therapy for Huntington’s, a devastating disease that leads to complete physical and mental deterioration. That asset, BV-101, is about to enter the clinic.
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.
Public Company Edition: The stock market has been unkind to biotech firms but investors rewarded some drug developers for clinical trial successes, including Scholar Rock and Day One, which raised $205m and $172.5m, respectively. However, some SPAC deals and an IPO never got off the ground.
- Medical Devices
- Large Molecule
- Other Names / Subsidiaries
- Antigen Express, Inc.
- Grainland Pharmacy LLC
- Hema Diagnostic Systems, LLC
- Medisource Partners
- NuGenerex Distribution Solutions, LLC
- NuGenerex Immuno-Oncology
- Pantheon Medical
- Pantheon Medical – Foot & Ankle
- Regentys Corporation
- Veneto Holdings, LLC